The immune system is known to play a vital role in the development and control of metastatic diseases. In recent years immunotherapies targeting either activation of effector CD8⁺ T cells or inactivation of regulatory T cells have been identified to aid in tumour regression and increase overall patient survival. Although these treatments have been promising in the clinic, their efficacy is restricted to a small group of responders. To overcome this issue, we need ways to both increase CD8⁺ T cell recruitment and activity at the tumour. Innovative ways to manipulate the tumour environment need to be identified to increase patient response to immunotherapy. Our laboratory focuses on immune cell migration which is mediated by the chemokine system. Specifically, if the chemokine system can be modulated to increase tumour infiltration of effector CD8⁺ T cells or decrease the tumour infiltration of regulatory T cells then, there is potential for therapeutic use to improve the response to immunotherapy in patients who do not respond.